EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Long‐term imoxin treatment does not attenuate disease severity in dystrophic diaphragm of male mice

Ji Heun Lee iD, Morgan E Vorwald, Melissa Roths, Joshua T Selsby iD, Rudy J Valentine

Physiological Reports · 2026

DOI: 10.14814/phy2.71115 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Physiological Reports, 2026. Verfasst von Ji Heun Lee und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Kinesiology, Iowa State University, Ames, Iowa, USA. Hauptthemen laut MEDLINE: Muscular Dystrophy, Duchenne, Diaphragm. Die Arbeit nennt 68 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAMS NIH HHS, HHS | National Institutes of Health (NIH).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Duchenne muscular dystrophy (DMD) is characterized by chronic skeletal muscle injury and degeneration. We discovered activation of protein kinase R (PKR; EIF2AK2), a regulator of the integrated stress response, in dystrophic muscle; however, its role in DMD remains unknown. We hypothesized that the PKR inhibitor imoxin (IMX) would improve muscle force and attenuate fibrosis, inflammatory signaling, and ER stress in diaphragms from mdx mice. C57 and mdx mice were treated with vehicle or IMX for ~24 wks (0.5 mg/kg, subcutaneous, 5 times/wk). Specific force was decreased ( p < 0.001), and dynamic passive force was increased ( p = 0.001) by disease, but there were no IMX effects. Disease‐increased fibrotic area was decreased by IMX ( p = 0.038); however, IMX failed to reduce fibronectin, collagen, or TGF‐β1 signaling proteins. PKR and phosphorylated (p)PKR (thr446) were increased in mdx ( p < 0.001) and maintained despite IMX treatment. Similarly, PKR regulators (total PACT, pPACT (ser18), TRBP, and PP1α), and PKR substrates (total eIF2α and peIF2α (ser51)) were also increased with disease ( p < 0.001), but unaffected by IMX. Likewise, IMX did not attenuate disease‐mediated elevations in inflammatory signaling and ER stress markers. Overall, the dose of IMX was insufficient to attenuate PKR activation and failed to improve muscle function or prevent pathology in dystrophic skeletal muscle.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Muscular Dystrophy, DuchenneDiaphragmAnimalsMaleMice, Inbred mdxMice, Inbred C57BLeIF-2 KinaseMiceEndoplasmic Reticulum StressFibrosisSignal TransductionImidazolesIndoles

Stichwörter der Autor:innen

DMDDuchenne muscular dystrophyER stressdystrophinprotein kinase R

Substanzen

eIF-2 KinaseimoxinImidazolesIndoles

Autor:innen und Institutionen

  • Department of Kinesiology, Iowa State University, Ames, Iowa, USA.
  • Department of Animal Science, Iowa State University, Ames, Iowa, USA.
  • Department of Physical Therapy & Kinesiology, University of Massachusetts Lowell, Lowell, Massachusetts, USA.

ORCID-Profile: Ji Heun Lee, Joshua T Selsby

Förderung

  • NIAMS NIH HHS
  • HHS | National Institutes of Health (NIH)

Zitieren

APA

Lee, J. H., Vorwald, M. E., Roths, M., Selsby, J. T., & Valentine, R. J. (2026). Long‐term imoxin treatment does not attenuate disease severity in dystrophic diaphragm of male mice. Physiological Reports. https://doi.org/10.14814/phy2.71115

Vancouver

Lee JH, Vorwald ME, Roths M, Selsby JT, Valentine RJ. Long‐term imoxin treatment does not attenuate disease severity in dystrophic diaphragm of male mice. Physiological Reports. 2026. doi:10.14814/phy2.71115

BibTeX
@article{Lee2026,
  author = {Lee, Ji Heun and Vorwald, Morgan E and Roths, Melissa and Selsby, Joshua T and Valentine, Rudy J},
  title = {Long‐term imoxin treatment does not attenuate disease severity in dystrophic diaphragm of male mice},
  journal = {Physiological Reports},
  year = {2026},
  doi = {10.14814/phy2.71115}
}
Kostenlos starten →